Physician profile
Ignacio A Sotolongo
NPI 1760478846
$2,467.12
in general payments reported to CMS, 2019-2025
33 companies · $676 in 2025
The $676 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $23.84 · 2021: $417 · 2022: $355 · 2023: $22.53 · 2024: $322 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $972 · Education: $47.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $971.99 |
| Education | $47.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $245.46 | 2024-2025 | Ozempic, Rybelsus |
| Nxstage Medical, INC. | $228.43 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $222.91 | 2019-2025 | Farxiga |
| Mallinckrodt Enterprises LLC | $204.18 | 2019 | |
| Baxter Healthcare | $194.93 | 2019-2024 | Renal - Pd |
| Amgen INC. | $165.03 | 2019-2025 | Uplizna, Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $164.20 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $159.74 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $137.63 | 2019-2025 | Rayaldee |
| Akebia Therapeutics INC | $75.45 | 2019-2024 | Vafseo |
| Fresenius USA Marketing, INC. | $71.32 | 2019-2024 | Velphoro |
| Novartis Pharmaceuticals Corporation | $66.87 | 2019-2025 | |
| Vifor Pharma, INC. | $50.49 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $38.78 | 2024 | Acthar |
| Ardelyx, INC. | $32.28 | 2025 | Ibsrela |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $29.17 | 2025 | |
| Lilly USA, LLC | $28.69 | 2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.60 | 2025 | Jardiance |
| Smith+Nephew, INC. | $28.56 | 2025 | Collagenase Santyl |
| Calliditas Therapeutics US INC. | $28.53 | 2025 | Tarpeyo |
| 180 Medical, INC. | $28.35 | 2021 | |
| Glaxosmithkline, LLC. | $28.24 | 2025 | Benlysta |
| Kyowa Kirin, INC. | $27.28 | 2025 | |
| Ani Pharmaceuticals, INC. | $24.42 | 2022 | |
| Horizon Therapeutics Plc | $23.84 | 2020 | |
| Apellis Pharmaceuticals, INC. | $22.21 | 2025 | Empaveli |
| Davol INC. | $22.07 | 2025 | Arista |
| Terumo Medical Corporation | $16.45 | 2024 | Glidesheath Slender |
| Shire North American Group INC | $16.42 | 2019 | |
| Amarin Pharma, INC. | $15.88 | 2021 | |
| Genentech USA, INC. | $15.83 | 2019 | |
| Daiichi Sankyo INC. | $14.13 | 2025 | Injectafer |
| Biomerieux INC | $10.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ignacio Sotolongo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.